BioLineRx Ltd. (BLRX)

NASDAQ: BLRX · IEX Real-Time Price · USD
1.71
0.03 (1.79%)
Jan 28, 2022 1:31 PM EST - Market open
Market Cap85.74M
Revenue (ttm)n/a
Net Income (ttm)-34.74M
Shares Out50.14M
EPS (ttm)-0.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume101,548
Open1.67
Previous Close1.68
Day's Range1.67 - 1.76
52-Week Range1.67 - 6.34
Beta1.46
AnalystsBuy
Price Target14.50 (+748.0%)
Earnings Daten/a

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy fi...

IndustryBiotechnology
IPO DateJul 25, 2011
CEOPhilip Serlin
Employees38
Stock ExchangeNASDAQ
Ticker SymbolBLRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for BioLineRx stock is "Buy." The 12-month stock price forecast is 14.50, which is an increase of 747.95% from the latest price.

Price Target
$14.50
(747.95% upside)
Analyst Consensus: Buy

News

BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, ...

TEL AVIV, Israel, Jan. 24, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has comp...

4 days ago - PRNewsWire

BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in...

TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has co...

1 week ago - PRNewsWire

BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annua...

TEL AVIV, Israel, Dec. 17, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today provided updates from an oral prese...

1 month ago - PRNewsWire

BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)

TEL AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced establishment of a Scient...

1 month ago - PRNewsWire

BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF - - Pre-NDA meeting with FDA se...

2 months ago - PRNewsWire

BioLineRx to Report Third Quarter 2021 Results on November 18, 2021

TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaud...

2 months ago - PRNewsWire

BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (A...

TEL AVIV, Israel, Nov. 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced an oral presentation and t...

2 months ago - PRNewsWire

BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of C...

TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a p...

3 months ago - PRNewsWire

BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Aug. 18, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for t...

5 months ago - PRNewsWire

BioLineRx to Report Second Quarter 2021 Results on August 18, 2021

TEL AVIV, Israel, Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaud...

5 months ago - PRNewsWire

New Strong Sell Stocks for June 4th

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Other symbols:ASLNICMBMRNS
7 months ago - Zacks Investment Research

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for th...

8 months ago - PRNewsWire

BioLineRx to Report First Quarter 2021 Results on May 26, 2021

TEL AVIV, Israel, May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudi...

8 months ago - PRNewsWire

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Other symbols:CCXICOCP
8 months ago - Benzinga

BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment

Shares of BioLine RX Ltd. rocketed 60% toward a 2-year high in very active trading Tuesday, enough to pace all of the premarket gainers, after the biopharmaceutical company announced positive results fr...

8 months ago - Market Watch

BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myelo...

BioLineRx (NASDAQ: BLRX) has announced positive top-line results from GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, combined with granulocyte colony-stimulating factor (G-...

8 months ago - Benzinga

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization f...

TEL AVIV, Israel, May 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line results f...

8 months ago - PRNewsWire

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other symbols:APTXCYCNLCTXPTN
9 months ago - PennyStocks

BioLineRx Announces Presentation at 2021 American Association for Cancer Research (AACR) Annual Meeting

TEL AVIV, Israel, April 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has pre...

9 months ago - PRNewsWire

BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for t...

11 months ago - PRNewsWire

BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter

TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previo...

1 year ago - PRNewsWire

BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the u...

1 year ago - PRNewsWire

BioLineRx Announces $10 Million Bought Deal Offering

TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into ...

1 year ago - PRNewsWire

Why BioLine, Esperion And More Are Moving Today

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination w...

Other symbols:ESPRHTBX
1 year ago - Benzinga

BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Secon...

TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple c...

1 year ago - PRNewsWire